-
Mashup Score: 16Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy | Mission Bio - 2 month(s) ago
Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), a myeloid neoplasms that can evolve into acute myeloid leukemia (AML). However, our capacity to identify who
Source: missionbio.comCategories: General Medicine News, Future of MedicineTweet
Our @CRC_AACR @AACR article using @MissionBio #Tapestri #singlecell #multiomics (#DNA + #Protein) in longitudinal #myelodysplastic syndromes, highlighted by the company in its repository of publications: https://t.co/Q1spQHX9Os https://t.co/M5jCm5nBED